Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults, 18-60 years with sputum smear positive pulmonary TB~* New cases only~* Gender, both~* Consent to enroll in the study~Exclusion Criteria:~* Hypercalcaemia (serum calcium \> 2.6 mmol/L) identified at baseline~* Taking vitamin D~* Pregnant and lactating~* Any known liver or kidney function abnormality, malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Active Sodium Phenylbutyrate and active cholecalciferol (Type: ACTIVE_COMPARATOR): 500 mg sodium phenylbutyrate (4-phenylbutyric acid, sodium salt) in tablet form twice daily and 5000 IU of cholecalciferol once daily will be given orally for 2 months
- Placebo Sodium Phenylbutyrate plus active cholecalciferol (Type: ACTIVE_COMPARATOR): Drug: Cholecalciferol Placebo: Sodium Phenylbutyrate
- Active Sodium Phenylbutyrate and placebo cholecalciferol (Type: ACTIVE_COMPARATOR): Drug: Sodium Phenylbutyrate Placebo: cholecalciferol
- Placebo Sodium Phenylbutyrate plus placebo cholecalciferol (Type: PLACEBO_COMPARATOR): Placebo Sodium Phenylbutyrate Placebo cholecalciferol

Based on this trial design, predict the completion outcome and termination type (if applicable).